Dr Max Søgaard | Director, Process Development
ExpreS2ion Biotechnologies

Dr Max Søgaard, Director, Process Development, ExpreS2ion Biotechnologies

Following post-doctoral work in protein crystallography at University of Oxford, Max Søgaard joined Expres2ion Biotechnologies in 2013.  Working closely with clients he has helped to convert non-cGMP, lab-scale protocols into fully scalable, reproducible, cGMP compliant processes in a number of projects currently in clinical phase I/II trials.  His current focus is to expand the up- and downstream capabilities of the Expres2ion Biotechnologies protein production platform to meet the individual and diverse challenges of proteins for vaccine-antigens, diagnostics and therapeutics.  His pre-doctoral focus was within the field of basal transcription (Ph.D., Clare Hall, Cancer Research UK) as well as basal translation (Cand.Scient, University of Aarhus, Denmark).

Appearances:



April 16 Day 2 - 10 Co-conferences @ 12:55

ExpreS2 – An insect cell-based vaccine production system suitable for difficult-to-express proteins

last published: 25/Mar/19 13:35 GMT

back to speakers

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071